Atropisomer Control in Macrocyclic Factor VIIa Inhibitors

• Published in: Journal of medicinal chemistry Vol. 59; no. 8; pp. 4007 - 4018
• Main Authors: Glunz, Peter W, Mueller, Luciano, Cheney, Daniel L, Ladziata, Vladimir, Zou, Yan, Wurtz, Nicholas R, Wei, Anzhi, Wong, Pancras C, Wexler, Ruth R, Priestley, E. Scott
• Format: Journal Article
• Language: English
• Published: WASHINGTON American Chemical Society 28.04.2016; Amer Chemical Soc; American Chemical Society (ACS)
• Subjects: Chemistry, Medicinal; Crystallography, X-Ray; Factor VIIa - antagonists & inhibitors; Life Sciences & Biomedicine; Macrocyclic Compounds - chemistry; Macrocyclic Compounds - pharmacology; Magnetic Resonance Spectroscopy; Molecular Structure; Pharmacology & Pharmacy; Science & Technology; Serine Proteinase Inhibitors - chemistry; Serine Proteinase Inhibitors - pharmacology; ELUCIDATION; S2 SITE; NUCLEAR; SPECTROSCOPY; ACIDS; ENHANCEMENT
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.6b00244

Incorporation of a methyl group onto a macrocyclic FVIIa inhibitor improves potency 10-fold but is accompanied by atropisomerism due to restricted bond rotation in the macrocyclic structure, as demonstrated by NMR studies. We designed a conformational constraint favoring the desired atropisomer in which this methyl group interacts with the S2 pocket of FVIIa. A macrocyclic inhibitor incorporating this constraint was prepared and demonstrated by NMR to reside predominantly in the desired conformation. This modification improved potency 180-fold relative to the unsubstituted, racemic macrocycle and improved selectivity. An X-ray crystal structure of a closely related analogue in the FVIIa active site was obtained and matches the NMR and modeled conformations, confirming that this conformational constraint does indeed direct the methyl group into the S2 pocket as designed. The resulting rationally designed, conformationally stable template enables further optimization of these macrocyclic inhibitors.